Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection

NCT05867056 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Enrollment into the phase 2 portion was never initiated.

Conditions

Hepatitis B, Chronic

Interventions

DRUG: IMC-I109V Single Ascending Dose
DRUG: IMC-I109V Multiple Ascending Doses
DRUG: HBV HCC Module MAD

Sponsor

Immunocore Ltd